Artificial intelligence (AI) has become a key driving force for next generation innovation. Research has shown various examples of successful problem solving and the advent of high-performance computing power has led to A.I. being used in a wide spectrum of applications. There are already many commercial applications of A.I. and many corporates are competing with […]
This analysis was developed in partnership between Dr. Diu Seng See, Solution Consultant (Southeast Asia), Scientific and Academic Research and Ridhma Dhar, Solution Consultant (Southeast Asia), IP Solutions, both of Clarivate Analytics. Southeast Asia is one region that has invested heavily in Artificial Intelligence (AI) and as a result boasts huge growth in its AI […]
In part 3 of this blog series about best practices in toxicology, we continue the discussion from parts 1 & 2 that outlined elements in the discovery stage that could impact safety and how we can start considering a drug’s effects on toxicity of specific organs and specific patients via toxicogenomics, pharmacogenomics and pharmacoepigenomics. To help reach a deeper understanding of the mechanisms related to toxicity and subtle differences in the genetic makeup that influence the maximum tolerated drug dose or efficacy, we need to be able to access and process large quantities of experimental data, which can be facilitated by incorporating artificial intelligence (AI) and machine learning algorithms into data analysis workflows.
Artificial intelligence (AI), the ability of computer systems to simulate or imitate human intelligence, is quietly transforming our daily lives. But how does it work? And how does it benefit busy trademark professionals? We’ll answer these important questions in our latest white paper: Making sense of artificial intelligence.
From self-driving cars to ChatGPT and Amazon Bedrock, the world is quickly waking up to the enormous potential for artificial intelligence (AI) to change our world.
The question many Market Authorisation Holders (MAH) are asking themselves at the moment is how they can use artificial intelligence in pharmacovigilance literature review. The reason? Many MAHs face a growing challenge to reviewing scientific literature for Individual Case Safety Reports (ICSRs) caused by a rising volume of literature that needs to be assessed. To […]
Our latest report, Redefining AI: How IP Practice Meets the Coming Wave, puts the perception of AI front and center to understand what’s next for the IP.
Special collections are often the gem of a library and deserve to be easily accessible to library patrons. At Ex Libris, part of Clarivate, we are prioritizing this vision as we work on metadata enrichment via AI for digital resources. Special collections include unique material in a variety of formats, from rare historical documents to […]
Data quality and insights are at the heart of Clarivate IP solutions and is a critical foundation to any new AI. By leveraging our internal experts to support the development of training models we provide the worlds leading IP and R&D organizations with responsibly built AI-enhanced IP solutions that they can trust. Contact us today.